Patents by Inventor Adrian Hugenmatter

Adrian Hugenmatter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PH-DEPENDENT MUTANT INTERLEUKIN-2 POLYPEPTIDES
    Publication number: 20240092853
    Abstract: The present invention generally relates to pH-dependent mutant interleukin-2 polypeptides that exhibit reduced IL-2 receptor binding at neutral pH and retained IL-2 receptor binding at reduced pH. In addition, the invention relates to immunoconjugates comprising said pH-dependent mutant IL-2 polypeptides, polynucleotide molecules encoding the pH-dependent mutant IL-2 polypeptides or immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the pH-dependent mutant IL-2 polypeptides or immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.
    Type: Application
    Filed: December 2, 2021
    Publication date: March 21, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Lorenzo DEHO, Christian GASSNER, Sylvia HERTER, Thomas HOFER, Ralf HOSSE, Adrian HUGENMATTER, Christian KLEIN, Florian LIMANI, Ekkehard MOESSNER, Melanie OBBA, Bianca SCHERER, Pablo UMANA
  • HUMANIZED ANTI-TAU(PS422) ANTIBODIES AND METHODS OF USE
    Publication number: 20230265177
    Abstract: The invention provides humanized anti-human Tau(pS422) antibodies and methods of using the same.
    Type: Application
    Filed: December 29, 2022
    Publication date: August 24, 2023
    Inventors: Stefan Dengl, Thomas Emrich, Guy Georges, Ulrich Goepfert, Fiona Grueninger, Adrian Hugenmatter, Anton Jochner, Hubert Kettenberger, Joerg Moelleken, Ekkehard Moessner, Olaf Mundigl, Jens Niewoehner, Tilman Schlothauer, Michael Molhoj, Kevin Brady
  • Humanized anti-Tau(pS422) antibodies and methods of use
    Patent number: 11572404
    Abstract: The invention provides humanized anti-human Tau(pS422) antibodies and methods of using the same.
    Type: Grant
    Filed: September 17, 2020
    Date of Patent: February 7, 2023
    Assignee: Hoffman-La Rocher Inc.
    Inventors: Stefan Dengl, Thomas Emrich, Guy Georges, Ulrich Goepfert, Fiona Grueninger, Adrian Hugenmatter, Anton Jochner, Hubert Kettenberger, Joerg Moelleken, Ekkehard Moessner, Olaf Mundigl, Jens Niewoehner, Tilman Schlothauer, Michael Molhoj, Kevin Brady
  • HUMANIZED ANTI-TAU(PS422) ANTIBODIES AND METHODS OF USE
    Publication number: 20210139571
    Abstract: The invention provides humanized anti-human Tau(pS422) antibodies and methods of using the same.
    Type: Application
    Filed: September 17, 2020
    Publication date: May 13, 2021
    Inventors: Stefan Dengl, Thomas Emrich, Guy Georges, Ulrich Goepfert, Fiona Grueninger, Adrian Hugenmatter, Anton Jochner, Hubert Kettenberger, Joerg Moelleken, Ekkehard Moessner, Olaf Mundigl, Jens Niewoehner, Tilman Schlothauer, Michael Molhoj, Kevin Brady
  • Humanized anti-tau(pS422) antibodies and methods of use
    Patent number: 10822402
    Abstract: The invention provides humanized anti-human Tau(pS422) antibodies and methods of using the same.
    Type: Grant
    Filed: December 5, 2017
    Date of Patent: November 3, 2020
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Stefan Dengl, Thomas Emrich, Guy Georges, Ulrich Goepfert, Fiona Grueninger, Adrian Hugenmatter, Anton Jochner, Hubert Kettenberger, Joerg Moelleken, Ekkehard Moessner, Olaf Mundigl, Jens Niewoehner, Tilman Schlothauer, Michael Molhoj, Kevin Brady
  • MONOVALENT BLOOD BRAIN BARRIER SHUTTLE MODULES
    Publication number: 20200071413
    Abstract: Herein is reported a blood brain barrier shuttle module comprising a brain effector entity, a linker and one monovalent binding entity which binds to a blood brain barrier receptor, wherein the linker couples the effector entity to the monovalent binding entity which binds to the blood brain barrier receptor wherein the monovalent binding entity does not comprise the variable domains of the anti-transferrin receptor antibody 8D3 (SEQ ID NO: 01 and SEQ ID NO: 02) or of the variant anti-transferrin receptor antibody 8D3v (SEQ ID NO: 01 and SEQ ID NO: 03).
    Type: Application
    Filed: June 28, 2019
    Publication date: March 5, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Petra RUEGER, Georg TIEFENTHALER, Ekkehard MOESSNER, Jens NIEWOEHNER, Adrian HUGENMATTER, Cuiying SHAO, Francesca ROS, Gang XU
  • Monovalent blood brain barrier shuttle modules
    Patent number: 10364292
    Abstract: Herein is reported a blood brain barrier shuttle module comprising a brain effector entity, a linker and one monovalent binding entity which binds to a blood brain barrier receptor, wherein the linker couples the effector entity to the monovalent binding entity which binds to the blood brain barrier receptor wherein the monovalent binding entity does not comprise the variable domains of the anti-transferrin receptor antibody 8D3 (SEQ ID NO: 01 and SEQ ID NO: 02) or of the variant anti-transferrin receptor antibody 8D3v (SEQ ID NO: 01 and SEQ ID NO: 03).
    Type: Grant
    Filed: July 6, 2016
    Date of Patent: July 30, 2019
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Petra Rueger, Georg Tiefenthaler, Ekkehard Moessner, Jens Niewoehner, Adrian Hugenmatter, Cuiying Shao, Francesca Ros, Gang Xu
  • HUMANIZED ANTI-TAU(PS422) ANTIBODIES AND METHODS OF USE
    Publication number: 20180079804
    Abstract: The invention provides humanized anti-human Tau(pS422) antibodies and methods of using the same.
    Type: Application
    Filed: December 5, 2017
    Publication date: March 22, 2018
    Inventors: Stefan Dengl, Thomas Emrich, Guy Georges, Ulrich Goepfert, Fiona Grueninger, Adrian Hugenmatter, Anton Jochner, Hubert Kettenberger, Joerg Moelleken, Ekkehard Moessner, Olaf Mundigl, Jens Niewoehner, Tilman Schlothauer, Michael Molhoj, Kevin Brady
  • Humanized anti-tau(pS422) antibodies and methods of use
    Patent number: 9862763
    Abstract: The invention provides humanized anti-human Tau(pS422) antibodies and methods of using the same.
    Type: Grant
    Filed: June 22, 2016
    Date of Patent: January 9, 2018
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Stefan Dengl, Thomas Emrich, Guy Georges, Ulrich Goepfert, Fiona Grueninger, Adrian Hugenmatter, Anton Jochner, Hubert Kettenberger, Joerg Moelleken, Ekkehard Moessner, Olaf Mundigl, Jens Niewoehner, Tilman Schlothauer, Michael Molhoj, Kevin Brady
  • BISPECIFIC ANTIBODIES AGAINST CD3EPSILON AND BCMA
    Publication number: 20170327579
    Abstract: A bispecific antibody specifically binding to the extracellular domain of human BCMA and human CD3?, characterized in comprising a common antibody light chain is provided. Such bispecific antibody can be used as a medicament in the treatment of plasma cell disorders like Multiple Myeloma.
    Type: Application
    Filed: November 18, 2015
    Publication date: November 16, 2017
    Inventors: MINH DIEM VU, KLAUS STREIN, OLIVER AST, MARINA BACAC, PETER BRUENKER, TANJA FAUTI, ANNE FREIMOSER-GRUNDSCHOBER, RAFT HOSSE, ADRIAN HUGENMATTER, CHRISTIANE JAEGER, CHRISTIAN KLEIN, EKKEHARD MOESSNER, Samuel MOSER, Pablo UMANA
  • METHOD AND CONSTRUCTS FOR THE pH DEPENDENT PASSAGE OF THE BLOOD-BRAIN-BARRIER
    Publication number: 20170174776
    Abstract: Herein is reported a fusion polypeptide comprising i) at least one binding site, e.g. which comprises an antibody heavy chain variable domain and an antibody light chain variable domain, and which binds to an internalizing cell surface receptor, and ii) at least one pharmaceutically active compound, whereby the EC50-value of the binding pair that binds to an internalizing cell surface receptor determined at pH 5.5 is higher than the EC50-value of the same binding pair determined at pH 7.4 and its use for delivering a pharmaceutically active compound across the blood-brain-barrier.
    Type: Application
    Filed: December 1, 2015
    Publication date: June 22, 2017
    Applicant: Roche Glycart AG
    Inventors: Bernd Bohrmann, Per-Ola Freskgard, Adrian Hugenmatter, Erhard Kopetzki, Ekkehard Moessner, Jens Niewoehner, Hadassah Sumum Sade, Pablo Umaña
  • MONOVALENT BLOOD BRAIN BARRIER SHUTTLE MODULES
    Publication number: 20170051071
    Abstract: Herein is reported a blood brain barrier shuttle module comprising a brain effector entity, a linker and one monovalent binding entity which binds to a blood brain barrier receptor, wherein the linker couples the effector entity to the monovalent binding entity which binds to the blood brain barrier receptor wherein the monovalent binding entity does not comprise the variable domains of the anti-transferrin receptor antibody 8D3 (SEQ ID NO: 01 and SEQ ID NO: 02) or of the variant anti-transferrin receptor antibody 8D3v (SEQ ID NO: 01 and SEQ ID NO: 03).
    Type: Application
    Filed: July 6, 2016
    Publication date: February 23, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Petra RUEGER, Georg TIEFENTHALER, Ekkehard MOESSNER, Jens NIEWOEHNER, Adrian HUGENMATTER, Cuiying SHAO, Francesca ROS, Gang XU
  • HUMANIZED ANTI-TAU(pS422) ANTIBODIES AND METHODS OF USE
    Publication number: 20160376352
    Abstract: The invention provides humanized anti-human Tau(pS422) antibodies and methods of using the same.
    Type: Application
    Filed: June 22, 2016
    Publication date: December 29, 2016
    Inventors: Stefan Dengl, Thomas Emrich, Guy Georges, Ulrich Goepfert, Fiona Grueninger, Adrian Hugenmatter, Anton Jochner, Hubert Kettenberger, Joerg Moelleken, Ekkehard Moessner, Olaf Mundigl, Jens Niewoehner, Tilman Schlothauer, Michael Molhoj, Kevin Brady
  • Method and Constructs for the pH Dependent Passage of the Blood-brain-barrier
    Publication number: 20120282176
    Abstract: Herein is reported a fusion polypeptide comprising i) at least one binding site, e.g. which comprises an antibody heavy chain variable domain and an antibody light chain variable domain, and which binds to an internalizing cell surface receptor, and ii) at least one pharmaceutically active compound, whereby the EC50-value of the binding pair that binds to an internalizing cell surface receptor determined at pH 5.5 is higher than the EC50-value of the same binding pair determined at pH 7.4 and its use for delivering a pharmaceutically active compound across the blood-brain-barrier.
    Type: Application
    Filed: April 18, 2012
    Publication date: November 8, 2012
    Applicant: Roche Glycart AG
    Inventors: Bernd Bohrmann, Per-Ola Freskgard, Adrian Hugenmatter, Erhard Kopetzki, Ekkehard Moessner, Jens Niewoehner, Hadassah Sumum Sade, Pablo Umaña